Holger Eidtmann

23.8k total citations · 2 hit papers
123 papers, 8.7k citations indexed

About

Holger Eidtmann is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Holger Eidtmann has authored 123 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Oncology, 78 papers in Cancer Research and 42 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Holger Eidtmann's work include Breast Cancer Treatment Studies (69 papers), Cancer Treatment and Pharmacology (55 papers) and HER2/EGFR in Cancer Research (48 papers). Holger Eidtmann is often cited by papers focused on Breast Cancer Treatment Studies (69 papers), Cancer Treatment and Pharmacology (55 papers) and HER2/EGFR in Cancer Research (48 papers). Holger Eidtmann collaborates with scholars based in Germany, United States and Belgium. Holger Eidtmann's co-authors include Gϋnter von Minckwitz, J. Hilfrich, Christian Jackisch, Sibylle Loibl, Jens‐Uwe Blohmer, Jens Huober, Serban Dan Costa, Manfred Kaufmann, Michael Untch and Bernd Gerber and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Holger Eidtmann

120 papers receiving 8.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

2012 1.8k citations Gϋnter von Minckwitz, Michael Untch et al. Journal of Clinical Oncology profile →
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab

2015 432 citations Carsten Denkert, Paolo Nucíforo et al. profile →

Peers

Countries citing papers authored by Holger Eidtmann

Since Specialization

Citations

This map shows the geographic impact of Holger Eidtmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holger Eidtmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holger Eidtmann more than expected).

Fields of papers citing papers by Holger Eidtmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holger Eidtmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holger Eidtmann. The network helps show where Holger Eidtmann may publish in the future.

Co-authorship network of co-authors of Holger Eidtmann

This figure shows the co-authorship network connecting the top 25 collaborators of Holger Eidtmann. A scholar is included among the top collaborators of Holger Eidtmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Holger Eidtmann. Holger Eidtmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer 2016 ·Clinical Cancer Research ·Sibylle Loibl, Silvia Darb‐Esfahani, Jens Huober, Alexander C. Klimowicz, Jenny Furlanetto, Bianca Lederer, Arndt Hartmann, Holger Eidtmann, Berit M. Pfitzner, Peter A. Fasching, Katharina Tiemann, Christian Jackisch, Keyur Mehta, Gϋnter von Minckwitz, Michael Untch, Carsten Denkert	34
2	Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status 2015 ·Annals of Oncology ·Paolo Nucíforo, Claudia Aura, Eileen Holmes, Ludmila Prudkin, José Jiménez, Paula Felippe Martinez, (unknown), Lorena de la Peña, (unknown), Holger Eidtmann, Martine Piccart, Maurizio Scaltriti, José Baselga	27
3	Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes 2014 ·BMC Cancer ·Silvia Darb‐Esfahani, Gϋnter von Minckwitz, Carsten Denkert, Beyhan Ataseven, B. Högel, Keyur Mehta, (unknown), Thomas Rüdiger, Berit M. Pfitzner, K. Kittel, (unknown), Klaus Baumann, Roland Moll, Manfred Dietel, Holger Eidtmann, Christoph Thomssen, Sibylle Loibl	67
4	Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44) 2014 ·Annals of Surgical Oncology ·Bernd Gerber, Gϋnter von Minckwitz, Holger Eidtmann, Mahdi Rezai, Peter A. Fasching, Hans Tesch, Holm Eggemann, Iris Schrader, K. Kittel, Claus Hanusch, Christine Solbach, Christian Jackisch, Georg Kunz, Jens‐Uwe Blohmer, Jens Huober, Maik Hauschild, Valentina Nekljudova, Sibylle Loibl, Michael Untch	16
5	Response-Guided Neoadjuvant Chemotherapy for Breast Cancer 2013 ·Journal of Clinical Oncology ·Gϋnter von Minckwitz, Jens‐Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann, W. Eiermann, Bernd Gerber, Claus Hanusch, J. Hilfrich, Jens Huober, Christian Jackisch, Manfred Kaufmann, Sherko Kümmel, Stefan Paepke, Andreas Schneeweiß, Michael Untch, Dirk M. Zahm, Keyur Mehta, Sibylle Loibl	265
6	Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial 2013 ·Journal of Clinical Oncology ·Hatem A. Azim, Dominique Agbor‐Tarh, Ian Bradbury, Phuong Dinh, José Baselga, Serena Di Cosimo, James Greger, Ian Smith, Christian Jackisch, Sung‐Bae Kim, Bahriye Aktas, Chiun‐Sheng Huang, Peter Vuylsteke, Ruey Kuen Hsieh, Lydia Dreosti, Holger Eidtmann, Martine Piccart, Evandro de Azambuja	45
7	Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial 2013 ·Annals of Oncology ·Carsten Denkert, Sibylle Loibl, Berit Müller, Holger Eidtmann, Wolfgang Schmitt, W. Eiermann, B. Gerber, Hans Tesch, J. Hilfrich, Jens Huober, Tanja Fehm, Jana Barinoff, Christian Jackisch, Judith Prinzler, Thomas Rüdiger, E Erbstösser, Jens‐Uwe Blohmer, Jan Budczies, K. Mehta, Gϋnter von Minckwitz	172
8	Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro) 2013 ·Annals of Oncology ·Gϋnter von Minckwitz, Mahdi Rezai, Peter A. Fasching, Jens Huober, Hans Tesch, Ingo Bauerfeind, J. Hilfrich, Holger Eidtmann, B. Gerber, Claus Hanusch, Jens‐Uwe Blohmer, Serban Dan Costa, Christian Jackisch, Stefan Paepke, Andreas Schneeweiß, Sherko Kümmel, Carsten Denkert, K. Mehta, Sibylle Loibl, Michael Untch	51
9	Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group 2013 ·Breast Cancer Research and Treatment ·Hans‐Joachim Lück, Andreas du Bois, Sibylle Loibl, Iris Schrader, Jens Huober, V. Heilmann, Matthias W. Beckmann, (unknown), Christian Jackisch, Michael Hubalek, Barbara Richter, Elmar Stickeler, Holger Eidtmann, Christoph Thomssen, Michael Untch, (unknown), Tibor Schuster, Gϋnter von Minckwitz	19
10	Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44) 2013 ·Annals of Oncology ·B. Gerber, Sibylle Loibl, Holger Eidtmann, Mahdi Rezai, Peter A. Fasching, Hans Tesch, Holm Eggemann, Iris Schrader, K. Kittel, Claus Hanusch, R. Kreienberg, Christine Solbach, Christian Jackisch, Georg Kunz, Jens‐Uwe Blohmer, Jens Huober, Maik Hauschild, Valentina Nekljudova, Michael Untch, Gϋnter von Minckwitz	105
11	8O_PR MUCIN-1 Protein and Mrna Expression in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy 2012 ·Annals of Oncology ·Bruno V. Sinn, Gϋnter von Minckwitz, Carsten Denkert, Holger Eidtmann, Silvia Darb‐Esfahani, Antje Belau, Ralf Kronenwett, (unknown), K. Mehta, Sibylle Loibl	0
12	The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use 2012 ·Annals of Oncology ·W. Eiermann, Mahdi Rezai, Sherko Kümmel, Thorsten Kühn, M Warm, Kay Friedrichs, Andreas Schneeweiß, Susanne Markmann, Holm Eggemann, J. Hilfrich, Christian Jackisch, Isabell Witzel, Holger Eidtmann, (unknown), (unknown), Jens‐Uwe Blohmer	116
13	Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy 2011 ·Breast Care ·Xinrong Guo, Sibylle Loibl, Michael Untch, Volker Möbus, Kathrin Schwedler, Peter A. Fasching, Jana Barinoff, Frank Holms, Christoph Thomssen, Dirk M. Zahm, R. Kreienberg, Maik Hauschild, Holger Eidtmann, (unknown), Keyur Mehta, Gϋnter von Minckwitz, (unknown)	11
14	Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial 2010 ·Clinical Cancer Research ·Sabine Riethdorf, Volkmar Müller, Liling Zhang, Thomas Rau, Sibylle Loibl, Martina Komor, Marc Roller, Jens Huober, Tanja Fehm, Iris Schrader, J. Hilfrich, Frank Holms, Hans Tesch, Holger Eidtmann, Michael Untch, Gϋnter von Minckwitz, Klaus Pantel	398
15	0155 ICE study: Ibandronate with or without capecitabine in elderly patients with early breast cancer 2009 ·The Breast ·Toralf Reimer, (unknown), Jochem Potenberg, Bettina Conrad, (unknown), Marianne Just, Holger Eidtmann, G. Heinrich, Sibylle Loibl, Valentina Nekljudova, Gϋnter von Minckwitz	2
16	Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies 2006 ·Annals of Oncology ·H.T. Mouridsen, Seppo W. Langer, Jan Buter, Holger Eidtmann, Giovanni Rosti, Maike de Wit, Poul Knoblauch, (unknown), (unknown), Peter Bjødstrup Jensen, Giuseppe Giaccone	99
17	Anthracycline and trastuzumab in breast cancer treatment. 2004 ·PubMed ·Michael Untch, (unknown), Steffen Kahlert, (unknown), Holger Eidtmann, Andreas du Bois, H.G. Meerpohl, Christoph Thomssen, Nadia Harbeck, C Jackisch, R. Kreienberg, Günter Emons, D. Wallwiener, William H. Wiese, Gerhard Schäller, W. Kühn, M Muscholl, M. Pauschinger, Bernd Langer	6
18	Dose-Dense Biweekly Doxorubicin/Docetaxel Versus Sequential Neoadjuvant Chemotherapy with Doxorubicin/Cyclophosphamide/Docetaxel in Operable Breast Cancer: Second Interim Analysis 2002 ·Clinical Breast Cancer ·Christian Jackisch, Gϋnter von Minckwitz, Holger Eidtmann, Serban Dan Costa, Günther Raab, Jens‐Uwe Blohmer, Martin Schütte, Bernd Gerber, E. Merkle, G. Gademann, Dieter Lampe, J. Hilfrich, (unknown), Angelika Caputo, Manfred Kaufmann	36
19	Krankheitsverlauf bei 551 Patientinnen mit nodal negativem Mammakarzinom 1992 ·Geburtshilfe und Frauenheilkunde ·Holger Eidtmann, W. Jonat, Carol A. Lange, Kay Friedrichs, H. Maaß	0
20	Betreuung einer Risikoschwangerschaft nach Lebertransplantation aus der Sicht des Geburtshelfers 1991 ·Geburtshilfe und Frauenheilkunde ·Andreas F. Kopp, (unknown), Holger Eidtmann, (unknown), (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact